Search results for " THROMBOSIS"

showing 10 items of 328 documents

Absence of residual vein thrombosis after an episode of idiopatic deep vein thrombosis: short-term anticoagulation is safe. The extended DACUS Study

2009

Abstract Background. The optimal duration of Oral Anticoagulant Therapy (OAT) for Deep Vein Thrombosis (DVT) can be tailored by Residual Vein Thrombosis (RVT) (Siragusa S et al. Blood2003;102(11):OC183), a marker able to assess the individual risk for recurrent thrombosis. However, in patients with idiopathic DVT the safety of early interruption of OAT, because of absence of RVT, is still debated. Objective of the study. In the present study, we evaluated the safety of withholding OAT, in patients with idiopathic DVT and without RVT, three months after the index thrombotic episode. Study design. Prospective controlled study with two groups: patients without RVT stopped OAT after 3 months wh…

medicine.medical_specialtyDeep veinImmunologyPopulationThrombophiliaBiochemistrydeep vein thombosis anticoagulationSettore MED/15 - Malattie Del SanguemedicineVeineducationFirst episodeeducation.field_of_studyresidual vein thrombosisbusiness.industrydeep vein thrombosiCell BiologyHematologymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisSurgeryPulmonary embolismVenous thrombosismedicine.anatomical_structurebusiness
researchProduct

Global public awareness about atrial fibrillation

2017

Essentials Early recognition of atrial fibrillation helps in stroke prevention. Survey in 10 countries to assess public awareness of atrial fibrillation. Overall global awareness of atrial fibrillation was 48%. Less than 46% of participants were aware atrial fibrillation leads to stroke. Background Atrial fibrillation (AF) is an important cause of ischemic stroke that often remains undetected until stroke occurs. Awareness of the risk factors and symptoms is important so that AF can be diagnosed and thromboprophylaxis given. However, the extent of public awareness of AF is uncertain. We assessed public awareness of AF across six continents and compared it with that of other thrombotic and n…

medicine.medical_specialtyDeep veinPopulationpopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinepreventionInternal medicinePalpitationsmedicineatrial fibrillationawarenesssurvey030212 general & internal medicineeducationStrokethrombosisPublic awarenesseducation.field_of_studybusiness.industryAtrial fibrillationHematologyglobalmedicine.diseaseThrombosisConfidence intervalmedicine.anatomical_structureinternationalEmergency medicineCardiologyOriginal Articlemedicine.symptombusinessOriginal Articles: ThrombosisResearch and Practice in Thrombosis and Haemostasis
researchProduct

Cocaine-induced coronary thrombosis and acute myocardial infarction

2004

A 26-year-old man was admitted to our hemodynamic laboratory because of an anterior AMI and post myocardial infarction angina. He is an active smoker (10 cigarettes/day) and consumes inhaled cocaine during weekends (the last consumption of cocaine was 1 week ago). No others risk factors were recorded. Initial electrocardiogram shows sinus rhythm and anterior QS complex (V1–V3) with anterolateral ST segment elevation (V1–V5, D1 and aVL). Creatine-kinase isoenzyme MB and Troponin I were elevated at arrival. Upon admission, the patient was normotensive but with signs of pulmonary congestion. Ventriculography showed anterolateral and apical hypokinesia with an ejection fraction of 21%. Coronari…

medicine.medical_specialtyEjection fractionbusiness.industryElectrocardiography in myocardial infarctionAnterior Descending Coronary Arterymedicine.diseaseThrombosisAnginaCoronary thrombosisRight coronary arterymedicine.arteryInternal medicinemedicineCardiologyMyocardial infarctionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis

2019

Abstract Background and aims Sex-specific differences exist for the initial presentation of acute venous thromboembolism (VTE): men are more likely to present with proximal deep vein thrombosis (DVT) in the lower limbs (versus pulmonary embolism [PE] or isolated distal DVT [IDDVT]) than women. We studied in detail the influence of sex, age, and VTE risk factors on the initial presentation of IDDVT versus proximal DVT. Methods A total of 24,911 patients with a first episode of objectively diagnosed acute symptomatic lower-limb DVT (without symptomatic PE) were enrolled in RIETE (years 2000–2017) and included in the present analysis. Results A total of 4266 (17.1%) patients had IDDVT. No tren…

medicine.medical_specialtyEpidemiologyDeep vein030204 cardiovascular system & hematologyDistal DVT03 medical and health sciences0302 clinical medicineDeep vein thrombosiDeep vein thrombosisInternal medicineEpidemiologymedicinecardiovascular diseasesFirst episodePregnancyProvoking risk factorsbusiness.industryCancerHematologymedicine.diseaseThrombosisPathophysiologyPulmonary embolismmedicine.anatomical_structureProvoking risk factor030220 oncology & carcinogenesisSexbusinessVenous thromboembolism
researchProduct

Predictive value of the Kuijer score for bleeding and other adverse in-hospital events in patients with venous thromboembolism

2021

Venous thromboembolism (VTE) constitute a major global burden of disease. Current international guidelines recommend treatment with anticoagulant therapy after VTE for a duration of at least 3 months. Since anticoagulation also imposes an increased risk for bleeding events, the individual risk has to be evaluated to determine adequate treatment plans.The nationwide German inpatient sample of the years 2005-2017 was used for this analysis. Hospitalized VTE patients were stratified according to Kuijer risk class and the performance of the Kuijer score was evaluated to predict adverse in-hospital events.Overall, 1,204,895 VTE patients were treated between 2005 and 2017 in Germany and were incl…

medicine.medical_specialtyHemorrhage030204 cardiovascular system & hematologyThrombophlebitis03 medical and health sciences0302 clinical medicineRisk FactorsInterquartile rangeGermanyInternal medicinemedicineHumansIn patientHospital Mortality030212 general & internal medicinebusiness.industryAnticoagulantsVenous ThromboembolismOdds ratiomedicine.diseaseHospitalsConfidence intervalPulmonary embolismVenous thrombosisCardiology and Cardiovascular MedicinebusinessVenous thromboembolismInternational Journal of Cardiology
researchProduct

Traps N' Clots: NET-Mediated Thrombosis and Related Diseases.

2020

medicine.medical_specialtyHypertension PulmonaryArterial Occlusive DiseasesGastroenterologyExtracellular TrapsAutoimmune DiseasesTranslational Research BiomedicalMiceInternal medicineNeoplasmsThromboembolismmedicineAnimalsHumansInflammationVenous Thrombosisbusiness.industryThrombosisHematologymedicine.diseasePlatelet ActivationThrombosisSystemic Inflammatory Response SyndromeEndothelium VascularbusinessForecastingThrombosis and haemostasis
researchProduct

Antiplatelet Therapy in Marathon Runners: More Harm than Benefits?

2013

We read with interest the article by Arthur J. Siegel, who recently concluded that prophylactic aspirin for primary prevention of cardiac events in marathon runners may be a viable approach for lowering the global risk of cardiovascular events in these subjects. Although there is a credible hysiological basis for supporting this provocative suggesion, and the use of nonsteroidal anti-inflammatory drugs is requent in athletes, there are, however, some issues that hould be considered, and which would globally overwhelm he hypothetical advantages of antiplatelet therapy in this eculiar setting. First, there is no controlled, randomized study that has efinitely proven the existence of any poten…

medicine.medical_specialtyMarathon runningantiplatelet therapylaw.inventionchemistry.chemical_compoundRandomized controlled triallawantiplatelet therapy; marathon race; harmAntithromboticmedicineAspirinNonsteroidalbiologyAthletesbusiness.industryGeneral Medicinebiology.organism_classificationmarathon raceHarmchemistryPhysical therapyAcute thrombosisbusinesshuman activitiesharmmedicine.drugThe American Journal of Medicine
researchProduct

Nuevos avances en el conocimiento del síndrome postrombótico

2003

La verdadera incidencia del síndrome postrombótico (SPT) no se conoce con precisión, aunque de la mayor parte de los estudios disponibles, parece deducirse que puede establecerse un año después de la trombosis venosa profunda (TVP) aguda de los miembros inferiores en el 17% al 50% de los pacientes. Inseparablemente unido a la hipertensión venosa que sigue al desarrollo de la incompetencia valvular, se acompaña de una serie de reacciones inflamatorias que incluyen el aumento de la permeabilidad endotelial, la unión de los leucocitos circulantes al endotelio, la infiltración por monocitos, linfocitos y mastocitos del tejido conectivo, y el desarrollo de infiltrados tisulares fibróticos y dist…

medicine.medical_specialtyMedical treatmentmedicine.diagnostic_testEndotheliumbusiness.industryIncidence (epidemiology)Magnetic resonance imagingSíndrome postrombóticomedicine.diseaseVenous ObstructionSurgeryVenous thrombosismedicine.anatomical_structureEco-dopplerClinical diagnosisAmbulatoryInternal Medicinemedicinebusiness
researchProduct

Coronary thrombolysis with tissue-type plasminogen activator (t-PA)

1985

Coronary thrombolysis is presently under intensive investigation as a treatment for acute myocardial infarction for two main reasons. Firstly it is now well established that acute myocardial infarction is often associated with thrombotic occlusion of an atherosclerotic coronary artery [1]. Secondly it has been shown that administration of thrombolytic agents can reopen an occluded coronary artery in the majority of patients [2, 3] and that reperfusion of ischemic myocardial tissue is generally well tolerated. Coronary thrombolysis is however not a goal in itself but is employed to prevent necrosis and dysfunction of jeopardized myocardial cells. There is ample evidence in animals that the i…

medicine.medical_specialtyNecrosisbusiness.industryCoronary reperfusionmedicine.diseasemedicine.anatomical_structureCoronary thrombosisInternal medicineCoronary thrombolysismedicineCardiologyThrombolytic AgentMyocardial infarctionmedicine.symptombusinessPlasminogen activatorArtery
researchProduct

Transarterielle Chemoembolisation (TACE) des Hepatozellulären Karzinoms (HCC) bei Patienten mit Pfortaderthrombose - Erfahrungen

2007

PURPOSE: Comparative analysis of the course of disease in patients with initial diagnosis of portal vein thrombosis in HCC treated with sequential TACE. Evaluation of the efficacy and safety of the method in a selected patient cohort. PATIENTS AND METHODS: The study included 22 patients with HCC that were palliatively treated at least 3 times with TACE. All patients presented a portal vein thrombosis in the initial CT investigation. The TACE-procedure was carried out in regular intervals using a suspension consisting of a fixed dosage of Mitomycin C (10 mg) and 10-20 ml Lipiodol. Follow-up investigations were carried out with contrast enhanced Multislice-CT before and after TACE and control…

medicine.medical_specialtyPalliative carebusiness.industryRetrospective cohort studymedicine.diseaseThrombosisGastroenterologyPortal vein thrombosisInternal medicineHepatocellular carcinomamedicineLipiodolSurgeryLiver functionRadiologybusinessContraindicationmedicine.drugZentralblatt für Chirurgie
researchProduct